Related Experiment Videos
Monoclonal antibody to the C-terminus of beta-amyloid
1Department of Medicine, UCLA.
Abstract:
Soluble amyloid beta-protein (A beta) is normally produced, but forms deposits in the brain of Alzheimer's (AD) patients. The length of isolated A beta in SDS-insoluble amyloid from AD brain is reported to vary between plaques and vessels ranging from 28 to 43, with major species being 40 and 42 residues. Because the A beta C-terminus determines aggregation rates, we made an A beta monoclonal antibody distinguishing beta 1-42 from beta 1-40. In AD cortex, the beta 1-42 antibody recognizes all the structures identified by monoclonal to beta 1-40 on adjacent sections: plaque cores, diffuse A beta deposits and vascular amyloid. These antibodies help define variation in A beta length between different deposits, regions and autopsied brains.
Insights
Researchers developed a new antibody to differentiate amyloid beta 1-42 from amyloid beta 1-40. This tool helps study variations in amyloid beta protein length within Alzheimer
Area of Science:
- Neuroscience
- Biochemistry
Background:
- Soluble amyloid beta-protein (A beta) is a normal product but forms deposits in Alzheimer's disease (AD) brains.
- A beta length varies in amyloid plaques and vessels (28-43 residues), with major species being 40 and 42 residues.
- The C-terminus of A beta influences its aggregation rates.
Purpose of the Study:
- To develop a tool to distinguish between amyloid beta 1-42 and amyloid beta 1-40.
- To investigate variations in A beta length in different AD pathological structures.
Main Methods:
- Development of a specific monoclonal antibody targeting the C-terminus of A beta 1-42.
- Immunohistochemical analysis of AD brain cortex using A beta 1-40 and A beta 1-42 antibodies on adjacent sections.
Main Results:
- The novel A beta 1-42 antibody recognized all structures identified by the A beta 1-40 antibody in AD cortex.
- Identified structures included plaque cores, diffuse A beta deposits, and vascular amyloid.
- Confirmed variations in A beta length across different deposit types, brain regions, and individuals.
Conclusions:
- The developed antibodies are valuable tools for characterizing A beta length heterogeneity in Alzheimer's disease.
- Understanding A beta length variations can provide insights into AD pathogenesis.
- Further research can utilize these antibodies to explore regional and individual differences in amyloid deposition.